PT-141 has one of the strangest origin stories in peptide science: a compound discovered because tanning-research volunteers kept reporting an unexpected side effect. Decades later, its refined successor became the first melanocortin receptor agonist approved for sexual dysfunction — a first-in-class FDA approval in 2019. This PT-141 research timeline traces the published history milestone by milestone: the University of Arizona tanning program, the accidental discovery, Palatin Technologies’ development campaign, the failed intranasal program, the pivot to an injectable formulation, and the phase 3 trials that ended in approval. It is a history of published research and regulatory events — not a guide to any use.
Research-use-only disclaimer: On this site, PT-141 (bremelanotide) is discussed as a research compound for laboratory and scientific investigation only. The approved medicine Vyleesi is a prescription drug; this article is a historical research summary, not medical information. It contains no dosage information, no usage instructions, and no medical advice.
PT-141 Research Timeline: The Milestones
Early 1960s — α-MSH and sexual arousal in rats
The PT-141 research timeline begins, improbably, with tanning-adjacent endocrinology: studies showed that administration of alpha-melanocyte-stimulating hormone (α-MSH) caused sexual arousal in rats. The observation sat in the literature for two decades — a curiosity about a pigmentation hormone with behavioral effects — until a group of chemists decided to build better versions of the hormone for an entirely different purpose.
1980s — The University of Arizona tanning program
Scientists at the University of Arizona began developing α-MSH and synthetic analogs as potential sunless tanning agents — compounds that would darken skin by mimicking the body’s own pigmentation hormone, potentially reducing skin-cancer risk for fair-skinned people. They synthesized and tested a series of analogs, including two peptides they named melanotan-I and melanotan-II. The goal was tanning. What they got, in addition, was the founding accident of the PT-141 research timeline.
Late 1990s — The accidental discovery
Very early in the melanotan program, scientist Mac Hadley conducted self-experiments with melanotan-II — and mistakenly administered himself twice the intended amount. The result was an eight-hour erection accompanied by nausea and vomiting. Other research subjects in the tanning studies reported similar unexpected effects: spontaneous arousal, in both men and women, without sexual stimulus. The researchers realized they had stumbled onto something the pharmaceutical industry had been chasing for decades — a compound acting on central arousal pathways rather than on vascular mechanics. The tanning program had accidentally produced a sexual-dysfunction lead.
2000 — Palatin synthesizes bremelanotide
Melanotan-II had been licensed to Palatin Technologies (via Competitive Technologies, the University of Arizona’s technology-transfer company). In 2000, Palatin ceased development of melanotan-II itself and instead synthesized, patented, and began developing bremelanotide — the compound the research world knows as PT-141. Chemically, bremelanotide is a cyclic heptapeptide lactam analogue of α-MSH, with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH: a likely metabolite of melanotan-II that differs in having a hydroxyl group where melanotan-II has an amide. Palatin had, in effect, isolated the arousal effect from the tanning molecule and rebuilt it as a dedicated research compound.
2004 — The King Pharmaceuticals partnership
In August 2004, Palatin signed a co-development agreement with King Pharmaceuticals to develop bremelanotide in the United States and jointly license it elsewhere; King paid Palatin $20 million upfront. With funding secured, Palatin advanced an intranasal formulation into Phase II trials for both female sexual dysfunction and male erectile dysfunction. The PT-141 research timeline now looked like a standard biotech development program — until the regulator intervened.
2007–2008 — The FDA halts the intranasal program
In 2007, the FDA halted the intranasal trials because of increased blood pressure in clinical trial subjects. Palatin stopped development of the intranasal formulation in 2008; King terminated the co-development agreement shortly after the halt. Four trials in erectile dysfunction had been conducted by then, the last a Phase IIb published in 2008. This was the near-death moment of the PT-141 research timeline: the lead indication, the lead formulation, and the lead partner all gone within about a year. Separately, Competitive Technologies sued Palatin over ownership of bremelanotide; the parties settled in 2008, with Palatin retaining bremelanotide rights, returning melanotan-II rights, and paying $800,000.
2008–2014 — Reformulation and the pivot to injection
Palatin reformulated bremelanotide for delivery by autoinjector and redirected the program toward female sexual dysfunction. A Phase II dose-finding trial, with the drug administered before anticipated sexual activity, showed promise at the highest dose with only transient blood-pressure signs. The pivot was a bet that the molecule was sound and the delivery format had been the problem. At the end of 2014, Palatin launched two Phase III trials — the studies that would decide the compound’s fate.
2014–2016 — European licensing and Phase III
In 2014, Palatin licensed European rights to Gedeon Richter for around $10 million, receiving a milestone payment of about $3 million when the US Phase III trials started. The partnership ended in September 2016 when the agreement was terminated. Two months later, in November 2016, Palatin announced the Phase III results — and began seeking a partner to complete US development.
2017–2018 — The AMAG deal and the NDA
In January 2017, Palatin and AMAG Pharmaceuticals agreed that AMAG would exclusively complete development and market bremelanotide in North America: $60 million upfront, up to $80 million in regulatory milestones, up to $300 million in sales milestones, plus tiered royalties. Palatin submitted the New Drug Application on March 26, 2018; the FDA accepted it for review on June 4, 2018, setting a PDUFA goal date of March 23, 2019. After the 2007 halt, the PT-141 research timeline had reached the final regulatory gate.
June 21, 2019 — FDA approval as Vyleesi
The FDA approved bremelanotide in June 2019 under the brand name Vyleesi, for hypoactive sexual desire disorder (HSDD) in premenopausal women — and designated it a first-in-class medication, meaning its mechanism was novel and different from previously approved drugs. From tanning-lab accident to first-in-class approval, the journey had taken roughly two decades. The PT-141 research timeline is one of the few peptide-research stories with an FDA approval at the end of it.
What “first-in-class” means: The FDA’s first-in-class designation describes the novelty of the mechanism — bremelanotide was the first approved melanocortin receptor agonist for sexual dysfunction — not a judgment of superiority over other treatments. It is a regulatory classification about how the drug works, not how well.
The Science Along the Way: What Researchers Established
The PT-141 research timeline is not only a business history; the published research established a pharmacological profile that is worth summarizing factually.
| Property | What the published record reports |
|---|---|
| Chemical class | Cyclic heptapeptide lactam analogue of α-MSH |
| Receptor pharmacology | Non-selective melanocortin receptor agonist (MC1–MC5 except MC2), acting primarily at MC3 and MC4 receptors |
| Mechanistic distinction | Acts centrally on melanocortin pathways rather than on vascular mechanics — the basis of its difference from PDE5 inhibitors |
| Elimination half-life | Approximately 2.7 hours |
| Phase 3 program | Two Phase III trials (RECONNECT) in premenopausal women with HSDD |
| Most common adverse event in Phase 3 | Nausea (40.0%), followed by flushing (20.3%) and headache (11.3%) |
| Regulatory status | FDA-approved June 21, 2019, as Vyleesi for HSDD in premenopausal women; first-in-class designation |
A note on the trial results, stated as the literature states it: researchers have questioned the rating scales and effect sizes on which bremelanotide was assessed, concluding benefits may be modest. The published record supports approval as a regulatory fact while sustaining scientific debate about magnitude — both belong in an honest PT-141 research timeline. Background on the compound is available at Wikipedia’s bremelanotide entry, and trial registry data at ClinicalTrials.gov lists ten registered bremelanotide studies, including the completed Phase III trials.
Men and PT-141: Early Phase II trials studied bremelanotide in men with erectile dysfunction, including men who had not responded to PDE5 inhibitors — but the program never advanced to Phase III in men, and the compound is not approved for male sexual dysfunction. The published PT-141 research timeline for men ends at Phase II.
Why This Timeline Matters for Peptide Researchers
The PT-141 research timeline is instructive beyond its own compound, because it compresses several classic drug-development lessons into one story:
- Serendipity needs a prepared observer. The tanning program could have dismissed the arousal reports as noise; instead, researchers recognized a central mechanism worth isolating.
- The molecule is not the formulation. The intranasal program died on blood-pressure signals in 2007; the same molecule in a reformulated delivery format reached approval twelve years later.
- Regulatory setbacks are not always terminal. An FDA clinical hold ended the lead program and the lead partnership — and the compound still reached the market through a different indication and delivery format.
- First-in-class cuts both ways. A novel mechanism earned the designation but also meant no regulatory precedent; every step from the 2007 hold to the 2019 approval was negotiated without a template.
Research framing: On this site, PT-141 is discussed as a research compound in the same lane as our other peptide research overviews — such as the selank vs semax comparison and our guides to selank nasal spray and semax nasal spray research. The approved medicine Vyleesi is a prescription product outside this site’s research-use scope; nothing here is information about using it.
Key Takeaways: PT-141 Research Timeline
1. It began as a tanning-research accident. The PT-141 research timeline starts with University of Arizona α-MSH analogs in the 1980s and a self-experiment gone sideways — a pigmentation program that accidentally discovered a central arousal mechanism.
2. Palatin rebuilt the molecule around the effect. In 2000, Palatin set melanotan-II aside and developed bremelanotide — a cyclic heptapeptide refined to carry the melanocortin activity without the tanning program’s baggage.
3. The program nearly died in 2007–2008. The FDA halted intranasal trials over blood-pressure signals, the King partnership ended, and ownership was litigated. Reformulation for injection and a pivot to female sexual dysfunction saved it.
4. Approval came in 2019 — first-in-class. After two Phase III trials, an AMAG partnership, and NDA review, the FDA approved bremelanotide as Vyleesi for HSDD in premenopausal women, designating it first-in-class. Scientific debate about effect size continues alongside the regulatory fact.
Research framing only — a historical summary of published research and regulatory events, not medical information or a usage recommendation.
PT-141 Research Timeline: Final Research Notes
Few research programs survive their own near-death. The PT-141 research timeline runs from rat studies in the 1960s through a tanning lab in the 1980s, a dosing accident in the 1990s, a biotech build-out in the 2000s, a regulatory halt that killed the lead program, and a twelve-year rebuild that ended in a first-in-class FDA approval in 2019. It is the rare peptide story with a complete arc — discovery, development, failure, reformulation, approval — and that completeness is what makes it worth studying.
For researchers, the timeline’s real value is structural: it shows how a compound’s fate can hinge less on its pharmacology than on formulation, indication selection, and persistence through regulatory setbacks. The molecule that reached the pharmacy in 2019 was, chemically, the same cyclic heptapeptide Palatin patented in 2000. Everything else — the delivery format, the indication, the partner, the trial design — was rebuilt around it. That is the lesson the PT-141 research timeline offers to anyone working with research peptides today.
Our Semax 10mg and Selank 10mg research listings carry the same research-use-only framing as this article. Compound background is available at Wikipedia, and the FDA’s public resources explain what approval and first-in-class designation mean.
PT-141 Research Timeline: Frequently Asked Questions
Quick answers to the questions researchers ask most about this history — all in research framing.
What is the PT-141 research timeline in brief?
Early 1960s: α-MSH linked to arousal in rats. 1980s: University of Arizona develops melanotan-I and II as tanning agents. Late 1990s: arousal side effects discovered, including a notable self-experiment. 2000: Palatin synthesizes bremelanotide (PT-141). 2004: King Pharmaceuticals partnership. 2007–2008: FDA halts intranasal trials; program pivots to an injectable formulation. 2014: Phase III trials launch. 2017: AMAG partnership. June 21, 2019: FDA approval as Vyleesi — first-in-class.
How was PT-141 discovered?
By accident. Researchers developing melanotan-II as a sunless tanning agent noticed test subjects reporting spontaneous arousal. Scientist Mac Hadley’s self-experiment with a double dose produced a prolonged, well-documented effect. Palatin Technologies then isolated the melanocortin activity into a dedicated compound — bremelanotide, or PT-141 — setting aside the tanning application.
Why did the FDA halt PT-141 trials in 2007?
The FDA halted the intranasal Phase II program because of increased blood pressure in trial subjects. Palatin discontinued the intranasal formulation in 2008 and reformulated bremelanotide for autoinjector delivery, redirecting the program to female sexual dysfunction — the path that eventually led to approval.
When was PT-141 approved, and for what?
The FDA approved bremelanotide on June 21, 2019, under the brand name Vyleesi, for hypoactive sexual desire disorder (HSDD) in premenopausal women, with a first-in-class designation for its novel melanocortin-receptor mechanism. It is a prescription medicine; this article is a historical summary, not medical information.
Is PT-141 approved for men?
No. Early Phase II trials studied bremelanotide in men with erectile dysfunction, but the program never advanced to Phase III for men. The PT-141 research timeline for male indications ends at Phase II, and the compound holds no approval for male sexual dysfunction.
Where can researchers verify the PT-141 research timeline?
The history is summarized at Wikipedia’s bremelanotide entry, trial records are public at ClinicalTrials.gov (ten registered bremelanotide studies), and approval information is public through the FDA. Research compounds are discussed on this site for laboratory use only, as with our Semax 10mg and Selank 10mg listings.
